Adapting Traditional Drug Development Methods for Epigenetic Therapies- Peter Staller

Gerald Clarke

Peter Staller Director of Oncology Research at Epitherapeutics talks to Pharma IQ about the differences between traditional drug development techniques and those required for development of a epigenetic therapy. He also discusses epigenetics as a growing area for finding druggable targets and the maturity of the field. Have Your Say Rate this feature and give us your feedback in the comments section below  [inlinead]
To continue reading this story get free access